Scarica l'app Stockscreener
42.55
3.91%
-1.73
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Exact Sciences Schedules First Quarter 2025 Earnings Call - The Joplin Globe
Cancer Screening Leader Exact Sciences Sets Q1 2025 Earnings Date: Key Details Inside - Stock Titan
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - BioSpace
Revolutionary Cancer Test Achieves 95% Accuracy, Cuts Unnecessary Procedures by 40% - Stock Titan
Benchmark maintains Buy on Exact Sciences, price target at $65 By Investing.com - Investing.com South Africa
Benchmark maintains Buy on Exact Sciences, price target at $65 - Investing.com
Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion - TipRanks
High Growth Tech Stocks To Watch In The US March 2025 - Yahoo Finance
Should You Retain Exact Sciences Stock in Your Portfolio Now? - Yahoo Finance
Why Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Invest in Exact Sciences Corp. (EXAS)? - MSN
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN - Quantisnow
Former Exact Sciences COO Joins Sera Prognostics Board Amid Strategic Expansion - Stock Titan
"Pick Up Your Poop" F Cancer's New Campaign Encourages At-Home Colorectal Cancer Screening - WV News
RBC Capital Initiates Coverage of Exact Sciences (BMV:EXAS) with Sector Perform Recommendation - Nasdaq
Commit To Buy EXACT Sciences At $30, Earn 14% Using Options - Nasdaq
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - Business Wire
Exact Sciences initiated with a Sector Perform at RBC Capital - TipRanks
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Joplin Globe
Exact Sciences Triples Industry Average in Employee Engagement, Wins Prestigious Gallup Award - StockTitan
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX - Business Wire
Charles Schwab Investment Management Inc. Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Increased by Jones Financial Companies Lllp - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Exact Sciences at Raymond James Conference: Strategic Growth and Innovation - Investing.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
La Paloma CC: Set to host PGA Tour Champions' Cologuard Classic - The First Call
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS) - Yahoo Finance
Exact Sciences Corporation (EXAS): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Truist Financial Corp Sells 1,905 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
EXACT Sciences Corp. to Host Earnings Call - ACCESS Newswire
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Atria Wealth Solutions Inc. Takes $316,000 Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Heritage Investors Management Corp Has $4.29 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Generali Investments Towarzystwo Funduszy Inwestycyjnych Acquires 6,000 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Sanctuary Advisors LLC - Defense World
Exact Sciences (NASDAQ:EXAS) Price Target Cut to $70.00 by Analysts at Piper Sandler - MarketBeat
Exact Sciences (NASDAQ:EXAS) Shares Up 4.8% After Analyst Upgrade - MarketBeat
2 Stocks Down 59% and 34% to Buy and Hold - The Globe and Mail
Exact Sciences to Participate in March Investor Conferences - BioSpace
Exact Sciences price target raised to $73 from $70 at Scotiabank - TipRanks
Healthcare Spotlight: Exact Sciences Takes Center Stage at Two Major March Conferences - StockTitan
symbol__ Stock Quote Price and Forecast - CNN
Exact Sciences Stock Climbs After Strong Q2 Results - MSN
Bank of America Has Lowered Expectations for Exact Sciences (NASDAQ:EXAS) Stock Price - Defense World
Exact Sciences Reports Strong Revenue Growth in 2024 - TipRanks
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga
Exact Sciences Corp Earnings Call Highlights Growth - TipRanks
3.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):